Recently, molecular biomarkers including 1p/19q co-deletion, BRAF mutation, IDH1/2 mutation, and TERT mutation have been widely used for glioma diagnosis, treatment, and prognosis prediction [3]. The gene discussed is BRAF; the disease is central nervous system cancer.